Bangladesh Plans Tk 300 Crore Animal Vaccine Plant to Reduce Import Dependence

Bangladesh is exploring a major expansion of domestic veterinary vaccine manufacturing through a proposed Tk 300 crore facility in Bogura, following a feasibility-study proposal aimed at reducing the country’s substantial dependence on imported animal vaccines.

Bangladesh has initiated steps towards establishing a modern animal vaccine manufacturing facility estimated to cost approximately Tk 300 crore (Tk 3 billion), in an effort to strengthen domestic production capacity and reduce reliance on imported veterinary biologicals.

The Department of Livestock Services (DLS) has submitted a proposal to the Ministry of Fisheries and Livestock for a feasibility study. The proposal has received in-principle approval, although funding has not yet been released because the study has not been incorporated into the Annual Development Programme.

The proposed facility is expected to be considered at Gabtali in Bogura, where approximately 200 acres of land have been identified as potentially available.

The feasibility study is scheduled, according to DLS documents, to cover the period from 1 October 2026 to 31 March 2027. It will examine demand, operational requirements, project costs, plant design, laboratory equipment, reagents and the financial and economic viability of the proposed investment.

The initiative is significant for Bangladesh’s livestock and poultry sectors, which depend heavily on imported vaccines to protect animals against infectious diseases.

A substantial gap between vaccine demand and domestic production

According to DLS data cited in the report, Bangladesh has an estimated livestock and poultry population of approximately 46.5 crore animals.

Annual animal-vaccine demand is estimated at approximately 260 crore doses. Current domestic production is around 32 crore doses, equivalent to only 12.31% of the reported national requirement. The balance is met through imports, with annual expenditure estimated at approximately Tk 5,000 crore.

Bangladesh reportedly imports animal vaccines from 18 countries, including India, China, South Korea, Japan, the United States and several European suppliers. The figures highlight the scale of the country’s dependence on international vaccine supply chains and the potential value of expanding local manufacturing.

Existing manufacturing infrastructure

The Bangladesh Livestock Research Institute (BLRI), based in Savar, is identified as the principal public-sector institution with facilities to produce a broad range of animal vaccines. The DLS also operates a Biologics and Applied Research unit in Cumilla, although its vaccine-production capacity is more limited.

Both facilities are reported to operate infrastructure established approximately three decades ago. BLRI currently produces 17 types of vaccines. Demand for two additional vaccine categories has emerged, taking the reported national requirement to 19 types.

The proposed new facility is intended to address capacity and infrastructure limitations through modern manufacturing systems and improved production capability.

Vaccine-specific supply gaps

The imbalance between national demand and local production is particularly pronounced for several high-priority livestock and poultry vaccines.

The figures indicate that the domestic supply gap varies considerably by disease.

FMD vaccine production is particularly constrained: reported domestic output of 20–26 lakh doses is substantially below annual demand of approximately 3.5 crore doses. Ranikhet disease, duck plague and fowl cholera also show significant differences between estimated requirements and local production.

These gaps have direct implications for disease prevention, farm productivity and the cost of livestock production.

What the feasibility study needs to address

Establishing a modern animal vaccine facility involves considerably more than constructing a manufacturing building. The feasibility assessment will need to consider the entire biological manufacturing and quality-assurance ecosystem. Key requirements include:

1. Product prioritisation: The facility will need a clear production roadmap based on disease burden, animal population, vaccine demand and existing supply shortages.

2. Manufacturing technology: Infrastructure may need to cover antigen production, seed-lot systems, upstream processing, downstream purification, formulation, filling and packaging.

3. Quality control: Testing capacity for sterility, potency, identity, purity, safety and batch consistency will be essential.

4. Biosafety and containment: Facilities must be designed according to the biological risks associated with the organisms and production processes involved.

5. Regulatory capability: Product registration, manufacturing approvals, validation, pharmacovigilance and post-market monitoring will be important to ensure reliable vaccine performance.

6. Cold-chain distribution: Manufacturing capacity will have limited impact unless vaccines can be stored, transported and delivered under appropriate temperature conditions.

7. Skilled workforce: Veterinary microbiologists, immunologists, bioprocess engineers, quality-assurance specialists and regulatory professionals will be required.

Public-private partnerships could shape the project

The Bangladeshi government has indicated that increasing domestic production and encouraging public-private partnerships are important elements of its broader objective of reducing import dependence.

For the animal-health industry, this could create opportunities for technology providers, vaccine developers, contract manufacturers and suppliers of specialised laboratory equipment. Potential areas of collaboration include:

• Vaccine seed and strain technology.

• Antigen production platforms.

• Bioreactors and fermentation systems.

• Filtration and purification equipment.

• Formulation and fill-finish systems.

• Quality-control laboratories.

• Cold-chain and distribution infrastructure.

• Technical training and technology transfer.

Indian veterinary vaccine manufacturers and CDMOs could be relevant potential partners because of geographical proximity and experience in livestock and poultry biologicals. However, no specific partnership or procurement agreement has been announced.

Domestic manufacturing alone will not solve disease-control challenges

The proposed investment addresses an important supply-side constraint, but vaccine availability is only one component of effective disease prevention. Bangladesh will also need to strengthen farm-level biosecurity, vaccination coverage, disease reporting, veterinary infrastructure and farmer awareness.

Climate-related disease pressures, animal movement and inconsistent farm management can undermine the effectiveness of even a well-funded vaccination programme.

At the recent policy level, the government has emphasised the importance of research, innovation and trained scientific personnel. Agricultural experts have also highlighted the need for stronger farm management and direct farmer support.

Project status: feasibility stage, not yet an approved operating plant

The proposed Tk 300 crore facility should be understood as a project under development. The feasibility study has received in-principle approval, but the project has not yet secured the required Annual Development Programme allocation. Construction, equipment procurement, technology selection and commercial production remain future steps.

The proposed plant could become an important milestone in Bangladesh’s veterinary biologicals industry. Its eventual success, however, will depend on the quality of its technology, regulatory systems, manufacturing economics and ability to deliver safe and effective vaccines at scale.